Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen previously led the global clinical development of ADSTILADRIN at Ferring Pharmaceuticals and will now lead Relmada's planned Phase 3 SPECTRUM registrational program for NDV-01 in bladder cancer.
Relmada Therapeutics reported third quarter 2026 financial results and provided a corporate update on its NDV-01 and sepranolone programs. The company ended the quarter with $202.1 million in cash, which is expected to fund operations through 2029, and remains on track to submit an IND for NDV-01 by year-end 2026.
“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program.”
Sergio Traversa, Chief Executive Officer of Relmada Therapeutics
“Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability. Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance.”
Bipin Dalmia, Chief Business Officer of Relmada Therapeutics
Relmada Therapeutics reported a net loss of $45.8 million for the nine months ended September 30, 2026, compared to $37.5 million in the prior year, driven by increased research and development costs. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $202.1 million in cash and short-term investments.